TrialPloS one2013

A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.

Alphonse Ouédraogo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.